Saturday 21 December 2024
Internal Reference Number: FOI_6760
Date Request Received: 31/08/2022 00:00:00
Date Request Replied To: 20/09/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer Treatment
Request Category: Private Individuals
| Question Number 1: In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with: • Abemaciclib (Verzenios) + aromatase inhibitor * • Abemaciclib (Verzenios) + Fulvestrant (Faslodex) • Alpelisib (Piqray) + Fulvestrant (Faslodex) • Atezolizumab (Tecentriq)** • Bevacizumab (Avastin) • Eribulin (Halaven) • Everolimus (Afinitor) + Exemestane • Fulvestrant (Faslodex) as a single agent • Gemcitabine + paclitaxel • Herceptin (Trastuzumab) + paclitaxel • Herceptin (Trastuzumab) as a single agent • Lapatinib (Tyverb) • Neratinib (Nerlynx) • Olaparib (Lynparza) • Palbociclib (Ibrance) + aromatase inhibitor* • Palbociclib (Ibrance) + Fulvestrant (Faslodex) • Pertuzumab (Perjeta) + trastuzumab + docetaxel • Ribociclib (Kisqali) + aromatase inhibitor* • Ribociclib (Kisqali) + Fulvestrant (Faslodex) • Talazoparib (Talzenna) • Trastuzumab emtansine (Kadcyla) • Other active systemic anti-cancer therapy ** *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent | |
| Answer To Question 1: Q. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with: • Abemaciclib (Verzenios) + aromatase inhibitor * <5 • Abemaciclib (Verzenios) + Fulvestrant (Faslodex) <5 • Alpelisib (Piqray) + Fulvestrant (Faslodex) 0 • Atezolizumab (Tecentriq)** 0 • Bevacizumab (Avastin) 0 • Eribulin (Halaven) 5 • Everolimus (Afinitor) + Exemestane <5 • Fulvestrant (Faslodex) as a single agent 0 • Gemcitabine + paclitaxel 0 • Herceptin (Trastuzumab) + paclitaxel 0 • Herceptin (Trastuzumab) as a single agent <5 • Lapatinib (Tyverb) 0 • Neratinib (Nerlynx) <5 • Olaparib (Lynparza) <5 • Palbociclib (Ibrance) + aromatase inhibitor* 35 • Palbociclib (Ibrance) + Fulvestrant (Faslodex) 5 • Pertuzumab (Perjeta) + trastuzumab + docetaxel <5 • Ribociclib (Kisqali) + aromatase inhibitor* 0 • Ribociclib (Kisqali) + Fulvestrant (Faslodex) 0 • Talazoparib (Talzenna) 0 • Trastuzumab emtansine (Kadcyla) <5 • Other active systemic anti-cancer therapy ** 35 *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent A. No answer made yet | |
| Question Number 2: For the above patients, how many of these received their first ever dose for each product line? | |
| Answer To Question 2: 19 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
